Oral vinorelbine plus cisplatin with concomitant radiotherapy as induction therapy for stage III non-small cell lung cancer: Results of a single-arm prospective cohort study

Ping-Chih Hsu1, John Wen-Chang Chang2, Chun-Chieh Wang3, Chen-Te Wu4, Yu-Ching Lin5, Chih-Liang Wang1, Tin-Yu Lin1, Shih-Hong Li7, Yi-Chen Wu7, Scott Chih-Hsi Kuo1, Cheng-Ta Yang1, Chien-Ying Liu1, Chih-Hung Chen1

1 Division of Thoracic Medicine, Department of Internal Medicine, Chang Gung Memorial Hospital at Linkou, Chang Gung University College of Medicine, Taoyuan City, Taiwan
2 Department of Oncology, Chang Gung Memorial Hospital Linkou branch, Taoyuan City, Taiwan
3 Division of Radiation Oncology, Chang Gung Memorial Hospital at Linkou, Chang Gung University College of Medicine, Taoyuan City, Taiwan
4 Department of Radiology, Chang Gung Memorial Hospital at Linkou, Chang Gung University College of Medicine, Taoyuan City, Taiwan
5 Division of Thoracic Oncology, Department of Respiratory and Critical Care Medicine, Chang Gung Memorial Hospital, Chiayi Branch, Chiayi county, Taiwan
6 Department of Respiratory Care, Chang Gung University of Science and Technology, Chiayi Campus, Chiayi county, Taiwan
7 Division of Thoracic and Cardiovascular Surgery, Department of Surgery, Chang Gung Memorial Hospital at Linkou, Chang Gung University College of Medicine, Taoyuan City, Taiwan
8 Department of Respiratory Therapy, College of Medicine, Chang Gung University, Taoyuan City, Taiwan

Keywords
Cisplatin; concurrent chemoradiotherapy; oral vinorelbine; stage III non-small cell lung cancer; survival.

Abstract
Background: Concurrent chemoradiotherapy (CCRT) is an optimal recommended treatment for stage III non-small cell lung cancer (NSCLC). Herein, we aimed to investigate the efficacy and safety of oral vinorelbine plus cisplatin with concomitant radiotherapy for stage III NSCLC.

Methods: This prospective, open-label, single-arm, observational cohort study was performed between January 2010 and September 2016. Patients were treated with two cycles of chemotherapy with 60 mg/m² intravenous cisplatin on day 1 and 50 mg/m² oral vinorelbine on days 1, 8, and 15; radiotherapy was administered concurrently from day 1 when chemotherapy was initiated. A total dose of 66–70 Gy radiotherapy was delivered in daily fractions of 2 Gy for 6.5–7 consecutive weeks. The tumor response was assessed after completing concomitant treatment.

Results: A total of 58 patients were enrolled and analyzed; 31 patients had stage IIIA NSCLC and 27 had stage IIIB NSCLC. After induction CCRT, 31 patients achieved an objective response (complete response in one and partial response in 30; the response rate was 53.4%). The median progression-free survival was 6.73 months (95% confidence interval [CI], 5.42–7.91), duration of response was 12.30 months (95% CI, 5.59–19.01), and overall survival was 24.83 months (95% CI, 19.26–30.21). No treatment-related mortality was observed, and neutropenia was the most common grade 3 and 4 treatment-related toxicity (11 patients; 18.9%).

Conclusions: CCRT with the weekly regimen of oral vinorelbine plus triweekly cisplatin was effective and safe for stage III NSCLC.
**Introduction**

Non-small-cell lung cancer (NSCLC) accounts for approximately 85% of lung cancer cases, and is the main cause of cancer-related death worldwide. Approximately one-third of NSCLC patients present with locally advanced stage III disease at initial diagnosis.² Stage III NSCLC patients present with heterogeneous medical conditions, which range from locally and extensively unresectable tumors to apparently resectable tumors with occult microscopic mediastinal nodal metastases and bulky or multistation mediastinal nodal disease.³ The combination of chemotherapy (CT) and radiotherapy (RT) is optimal and the recommended therapeutic strategy for locally advanced stage III NSCLC.³–⁵ Furthermore, in a phase II clinical trial, researchers tested cisplatin (CDDP)-based combinations with a third-generation agent—including gemcitabine (GEM), paclitaxel (PCT), and vinorelbine (NVB)—as induction CT followed by concurrent chemoradiotherapy (CCRT) with the same agents for the induction therapy of unresectable stage III NSCLC.⁶ The three agents had similar efficacy when combined with CDDP, and these combinations had response rates ranging from 67% to 74% and one-year survival rates from 62% to 68%.⁶ However, the three agents had different safety profiles, and the CDDP-NVB combination had less toxicity than the other two combinations, especially with regard to grade 3–4 esophagitis (NVB, 25%; PCT, 39%; and GEM, 52%).⁶

Oral vinorelbine (NVBo) is a relatively new formulation, and NVBo and intravenous NVB have similar treatment efficacy and safety profiles for advanced NSCLC.⁷–⁹ NVBo and CDDP have been used as induction therapy followed by NVBo and CDDP with concomitant RT for stage III NSCLC; NVBo combined with CDDP was effective and well-tolerated (with a treatment completion rate of 87%) in stage III NSCLC patients.¹⁰,¹¹ CCRT may be a more effective strategy than sequential chemoradiotherapy for locally advanced NSCLC.¹² However, the efficacy and safety of NVBo in neo-adjuvant CCRT for locally advanced stage III NSCLC are under investigation in eastern Asian patients. Therefore, this study aimed to evaluate the efficacy and safety profile of CDDP plus NVBo in combination with RT for locally advanced stage III NSCLC.

**Methods**

**Patients**

This prospective, open-label, single-arm, observational cohort study was approved by the institutional review board (No. 99-1900A3). Patients in the study were enrolled from two centers: the Chang Gung Memorial Hospital in Linkou and the Chang Gung Memorial Hospital in Chiayi. All patients provided signed written informed consent before enrollment. The inclusion criteria were as follows: histologically and/or cytologically confirmed locally advanced stage III NSCLC; age between 20 and 80 years; surgically unresectable tumor as reviewed by radiologists, surgeons, and oncologists on a tumor board; at least one measurable lesion according to the RECIST criteria; Eastern Cooperative Oncology Group performance status (ECOG-PS) score ≤2; weight loss ≤10% within the past three months prior to screening; life expectancy ≥12 weeks per the judgment of investigators; hemoglobin ≥10 g/dL, neutrophils ≥1.5 × 10⁹/L, or platelets ≥100 × 10⁹/L; total bilirubin ≤1.5 × upper limit normal (ULN), transaminases <2.5 × ULN, or alkaline phosphatases <5 × ULN; and creatinine <1.4 mg/dL or creatinine clearance rate >60 ml/min. Patients were excluded if they had previously undergone surgery for NSCLC or had received RT, systemic CT, targeted therapy, or other anticancer drugs. The intent-to-treat (ITT) population was defined as all enrolled patients who received at least one dose of CDDP plus NVBo in combination with RT, and the ITT population was used for the evaluation of efficacy and safety.

The sample size was estimated assuming that the response rate of the treatment group and reference group would be 60% and 50%, respectively. A difference of 10% in response rates was considered to have no clinical significance. Thus, under a two-sided significance level of 0.05 and power of 80%, the estimated sample size was 84 patients.

**Treatment plan**

Bioequivalence studies have shown that 60 and 80 mg/m² NVBo is equivalent to 25 and 30 mg/m² of the intravenous formulation, respectively.²² The dose of CDDP and NVBo was adjusted according to two previous studies and the ethnicity of the patients in our study, all of whom were eastern Asian.¹⁰,¹¹ NVBo was administered at a dose of 50 mg/m² on days 1, 8, and 15, and CDDP was delivered intravenously at a dose of 60 mg/m² on day 1. RT was administered concurrently with the first two cycles of CT. A total dose of 66–70 Gy was delivered in daily fractions of 2 Gy for 6.5–7 consecutive weeks. The clinical RT target area consisted of the primary volume of the gross tumor and node, ipsilateral hilum region, and elective mediastinum for which the lower edge was 3.0 cm below the carina. The planning radiation target area was a margin plus the clinical RT target area to ensure that the prescribed dose precisely covered the lesion. The tumor response was assessed after completing the second cycle of concomitant treatment. Patients who achieved an objective response (complete response [CR]/partial response [PR]) after induction therapy and were willing to undergo
surgery were referred to the lung cancer tumor board for presurgery evaluation. Patients underwent resection if the lung cancer tumor board deemed surgery feasible after reviewing the clinical and imaging data. Patients who achieved an objective response (CR/PR) or stable disease (SD) but who could not undergo surgery received two additional cycles of consolidation therapy consisting of 60 mg/m² NVBo on days 1 and 8 and 60 mg/m² CDDP on day 1. Some patients who achieved an objective response after consolidation therapy and could undergo surgery after being re-evaluated by the lung cancer tumor board also underwent resection. All the patients were covered by the national health insurance (NHI) program of Taiwan for the treatments including CT, RT, and surgery. Treatment was discontinued if the disease progressed or if adverse effects were observed. The treatment plan is summarized in Figure 1.

**Efficacy and safety evaluations**

The parameters evaluated included response rate, time to disease progression, overall survival (OS), duration of response (DOR), and toxicity profile. The imaging tests used for treatment efficacy evaluation were computed tomography, positron emission tomography, and chest radiography. Computed tomography was performed at baseline, weeks 3–7 of the second CCRT cycle, and the end-of-study visit. Positron emission tomography was performed at baseline and during the preoperation evaluation for determining which tumors were potentially resectable after downstaging. Chest radiography was performed at baseline and at the investigating physician’s discretion during follow-up. Other imaging studies such as bone scintigraphy were also performed at the investigating physician’s discretion if clinically indicated. The treatment response was assessed according to version 1.1 of the Response Evaluation Criteria in Solid Tumors (RECIST). The objective response rate (CR + PR) was the primary endpoint of this study. The secondary endpoints of this study were progression-free survival (PFS), DOR, and OS. The time to disease progression was measured from the date of initial combination therapy to the date of the first disease progression or death. Patients who had not shown disease progression or died at the time of study completion and those who were lost to follow-up were considered censored on the date of the last tumor assessment. The DOR was measured from the first date on which CR or PR was observed to the first date when recurrent or progressive disease (PD) or death was documented. Patients with no documented progression after CR or PR were censored at the last date on which they were known to have had the CR or PR, respectively. The OS was defined as the time from the date of combination therapy to the date of death, regardless of the cause of death. Patients who were alive at the time of study completion were censored at the date of the last follow-up assessment. Survival and disease progression data were analyzed until December 2017. If death or progression had not occurred, the survival time and progression time were considered censored.

Safety evaluations included a physical examination as well as evaluating the vital signs, ECOG-PS, complete blood cell counts, serum biochemistry, and clinical safety. Toxicities and adverse events were graded according to the

---

**Figure 1** Treatment scheme of the study.
National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) version 3.0.14

Statistical analysis

The demographic and baseline characteristics were presented as the number for qualitative variables or median and range for quantitative variables as appropriate. Survival analysis was performed by using the Kaplan-Meier method, and the data were summarized as the number of cases, number of censored cases, median time point estimate, and the 95% CI for the median value. Treatment-related toxicity was coded by using a coding system, and the results were summarized in a frequency table by using categorization, causality, severity, and number of patients with at least one adverse event. All statistical analyses were performed by using GraphPad Prism (Version 5.0; GraphPad Software, San Diego, CA, USA).

Results

A total of 58 patients with locally advanced stage III NSCLC were enrolled between January 2010 and September 2016. Patient characteristics are shown in Table 1.

During induction CCRT, treatment was discontinued in three patients because of PD. Among the three patients who underwent incomplete CCRT, one patient received one cycle of CT and 3500 cGy RT, while the other two received two cycles of CT and 6000 cGy RT. The remaining 55 patients underwent the complete CCRT course, with CT treatment delay observed in 34 patients. In the 34 patients who experienced CT treatment delay, treatment delay occurred on day 8 during cycle 1 in one patient, on day 15 during cycle 1 in nine patients, on day 1 during cycle 2 in five patients, on day 8 during cycle 2 in five patients, and on day 15 during cycle 2 in 16 patients. Hematological toxicity was the main reason (24 events, 70%) for CT treatment delay, followed by suspected infections (seven events, 21%), patient decision (two events, 6%), and deterioration in renal function (one event, 3%).

A total of 40 patients received consolidation CT after induction CCRT, and 17 treatment delay events were noted during the consolidation CT course. Among the 17 treatment delay events, treatment delay occurred on day 8 during cycle 3 in three patients, on day 1 during cycle 4 in five patients, and on day 8 during cycle 4 in the remaining nine patients. Hematological toxicity was the main reason for treatment delay in eight patients (47%), and infection was the reason for treatment delay in six patients (35%). The reasons for treatment delay in the remaining three patients, included the patient’s decision in one case, grade 3 abnormal aspartate aminotransferase (AST) levels in another, and pulmonary embolism in one patient.

Response and efficacy

The response evaluation was analyzed in the ITT population (58 patients). One patient achieved CR and 30 patients achieved PR, and the overall objective response rate was 53.4%. A total of 22 patients (38%) had SD, and five (8.6%) had PD (Table 2). The median PFS of the ITT population was 6.73 months (95% CI, 5.42–7.91; Fig 2a). For treatment responders, the median DOR was 12.30 months (95% CI, 5.59–19.01; Fig 2b). The median OS was 24.83 months (95% CI, 19.26–30.21; Table 2; Fig 2c). The 29 patients with PD within seven months were further analyzed (Table S1). Metastasis was the most common cause of disease progression (58.5%), followed by clinical progression (24.1%) and local progression (20.7%). Among the 29 patients, 24 (82.8%) received at least one-line of systemic therapies including platinum-base doublet CT, single agent CT, and epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor (TKI) after disease progression (Table S2). The characteristics and clinical information of the 17 patients who underwent surgery are shown in Table 3. The study consort diagram is shown in Figure 3.

Safety

Among hematological toxicities, the only grade 3 and 4 adverse event was neutropenia (11 patients; 18.9%). No patient in this study experienced treatment-related grade
Table 2 Treatment response and outcomes of concurrent chemoradiotherapy (CCRT) and surgery

|                          | Total 58 |
|--------------------------|----------|
| CR                       | 1        |
| PR                       | 30       |
| SD                       | 22       |
| PD                       | 5        |
| Overall response rate (%)| 31/58 (53.4%) |
| Median PFS (months)      | 6.73 (95% CI [5.42–7.91]) |
| Median DOR (months)      | 12.30 (95% CI [5.59–19.01]) |
| Median survival (months) | 24.83 (95% CI [19.26–30.21]) |
| Patients received surgery after downstaging (%) | 17 (29.3%) |
| Types of surgery         |          |
| Pneumonectomy            | 1        |
| Lobectomy                | 14       |
| Segmentectomy            | 1        |
| Wedge resection          | 1        |
| Resection score          |          |
| R0                       | 17       |
| Nodal downstaging (to N1 or N0) | 15 |
| Pathological complete remission | 7 |

CR, complete response; DOR, duration of response; PD, progressive disease; PFS, progression-free survival; PR, partial response; SD, stable disease.

Discussion

The results of our observational study suggest that NVBo plus CDDP with concomitant RT (i.e., CCRT) is effective and safe for unresectable stage III NSCLC. NVBo plus CDDP with CCRT yielded a response rate of 53.4%, and the median OS was 24.83 months. In addition, no treatment-related death was observed and the main grade 3 and 4 anemia or thrombocytopenia. Only one patient experienced febrile neutropenia during treatment (Table 4). Among non-hematological toxicities, one patient each had grade 3 vomiting and grade 3 fatigue. Grade 3 abnormal AST elevation was observed in this study, but it recovered after treatment interruption (Table 4). A total of 20 patients had grade 1 and 2 RT-related pneumonitis. Two patients had grade 3 radiation pneumonitis and were treated with systemic steroid and other supportive care (oxygen); this complication was manageable and did not worsen. No treatment-related mortality occurred in this study.

![Figure 2](image-url) Median progression-free survival (PFS), duration of response (DOR), and overall survival (OS) of the intent-to-treatment (ITT) population. (a) The median PFS was 6.73 months (95% confidence interval [CI], 5.42–7.91). Median PFS = 6.73 months. (b) The median DOR was 12.30 months (95% CI, 5.59–19.01). Median DOR = 12.3 months. (c) The median OS was 24.83 months (95% CI, 19.26–30.21). Median OS = 24.83 months. (d) The median PFS of patients who underwent surgery was 25.67 months (95% CI, 25.41–57.39). Median PFS = 25.67 months.
and 4 treatment-related toxicity was neutropenia (18.9%).

The management of stage III NSCLC patients is complex, and a multi-modality treatment approach including CT in combination with RT or surgery is the optimal strategy. CCRT may be better than sequential chemoradiotherapy in improving the survival of locally advanced NSCLC patients. Theoretically, CT could induce the cell cycle to stay in the more radiation-sensitive G2/M phase and enhance radiation-induced cytotoxicity in cancer cells, thereby suggesting that CCRT is more effective for treating locally advanced NSCLC. NVB was as effective as gemcitabine and paclitaxel when combined with CDDP, and in fact, had a more preferred safety profile. Moreover, NVBo in combination with CDDP is effective for stage III NSCLC. The combination of CDDP and NVBo with optimal RT doses was safe with high rates of treatment completion (87%) and good efficacy. During the concomitant phase, 40 mg/m² NVBo was administered once a day on days 1 and 8, every three weeks, and 80 mg/m² CDDP was administered triweekly. In another study, 50 mg/m² NVBo on days 1–4 was feasible in combination with RT. Thus, on the basis of the results of these two studies, we adjusted the CDDP dose to 60 mg/m² every three weeks and 50 mg/m² NVBo was administered once a day on days 1, 8, and 15 every three weeks considering the factors of efficacy and ethnicity (all patients were eastern Asian).

Table 3 Characteristics of the 17 patients who underwent surgery

| No. | Age | Sex | Histology     | Tentative stage | Pathological nodal stage | FEV1(L) | Thoracostomy | N  | Outcome | Note                      |
|-----|-----|-----|---------------|------------------|-------------------------|---------|--------------|----|---------|---------------------------|
| 1   | 55  | Male | Squamous      | 3 1 IIIA         | Pneumonectomy           | 2.79    | 0            | Dead | Brain metastatic recurrence |
| 2   | 50  | Male | Squamous      | 4 3 IIIB         | Lobectomy               | 2.08    | 0            | Alive| Pathological complete remission |
| 3   | 58  | Male | NSCLC         | 2 2 IIIA         | Lobectomy               | 3.29    | 0            | Alive| Pathological complete remission |
| 4   | 71  | Male | Adenocarcinoma| 3 2 IIIA         | Lobectomy               | 1.5     | 0            | Dead | Intestinal metastatic recurrence |
| 5   | 62  | Female | Adenocarcinoma| 3 2 IIIA         | Lobectomy               | 2.88    | 0            | Alive| Pathological complete remission |
| 6   | 52  | Male  | Squamous      | 3 3 IIIB         | Lobectomy               | 2.84    | 0            | Alive| Pathological complete remission |
| 7   | 72  | Male  | Squamous      | 3 2 IIIA         | Lobectomy               | 1.93    | 0            | Dead | Die of pneumoniae |
| 8   | 62  | Male  | Squamous      | 3 3 IIIB         | Lobectomy               | 2.87    | 1            | Dead | Local recurrence |
| 9   | 79  | Male  | Squamous      | 2 2 IIIA         | Lobectomy               | 1.81    | 0            | Alive| Pathological complete remission |
| 10  | 64  | Male  | Squamous      | 4 1 IIIB         | Lobectomy               | 1.8     | 0            | Alive| Pathological complete remission |
| 11  | 61  | Male  | Squamous      | 3 3 IIIB         | Lobectomy               | 3.11    | 0            | Alive| Pathological complete remission |
| 12  | 50  | Male  | Adenocarcinoma| 2 2 IIIA         | Segmentectomy            | 2.72    | 0            | Dead | Recurrence with brain metastasis |
| 13  | 64  | Male  | Adenosquamous | 2 2 IIIA         | Lobectomy               | 1.8     | 0            | Alive| Pathological complete remission |
| 14  | 33  | Female | Adenocarcinoma| 4 2 IIIB         | Lobectomy               | 2.08    | 2            | Alive| Local recurrence |
| 15  | 61  | Male  | Squamous      | 4 2 IIIB         | Lobectomy               | 2.66    | 0            | Alive| Local recurrence |
| 16  | 50  | Male  | Squamous      | 4 2 IIIB         | Lobectomy               | 2.58    | 0            | Dead | Brain metastatic recurrence |
| 17  | 69  | Female | Squamous     | 3 1 IIIA         | Lobectomy               | 1.41    | 2            | Dead | Brain metastatic recurrence |
The overall response rate in our study was higher than that reported by Descourt et al. (53.4% vs. 41%) and similar to that reported by Krzakowski et al. (53.4% vs. 53.7%). However, the PFS was 6.7 months in this study, which was shorter than that reported in three other studies using the same CT regimen concomitant with RT. The PFS was 15 months for elderly patients in the study by Locher et al., 9.2 months in the study by Descourt et al., and 14 months in the study by Lerouge et al. In the study by Locher et al., 40 patients were included which is smaller than the number of patients in our study (n = 58), and the elderly patients included were strictly selected via a comprehensive geriatric assessment (CGA) with highly clinical stability. In contrast, most of the patients (93%) in our study had ECOG PS scores of one, indicating that they at least had some clinical symptoms (e.g., dyspnea and cough). These clinical symptoms may partly limit the physical activity of patients at the time of entry in our study, possibly being the reason for the shorter PFS in our study compared to the PFS in the study by Locher et al. The patients in the studies of Descourt et al. and Lerouge et al. were pretreated with induction systemic CT, indicating that the patients would have had at least SD status after induction CT prior to receiving CCRT. However, in our study, metastasis accounted for the most common cause of disease progression (58.5%), followed by clinical progression (24.1%) and local progression (20.7%) in the 29 patients whose disease progressed within seven months. In fact, 24 of the 29 (82.8%) patients received systemic therapies after disease progression. Thus, this may explain why despite the short PFS in our study (6.7 months), the OS of our study was not inferior to those in the other three studies (24.8 vs. 21.8 vs. 20.8 vs. 17.1 months).

To our knowledge, our study is the first to show the efficacy and safety of NVBo plus CDDP with concomitant RT for pan-eastern Asian patients with stage III NSCLC. Previous studies were mainly carried out on European patients, while the present study was performed on eastern Asian patients. Taxanes (e.g., paclitaxel and docetaxel) are frequently used in combination with CDDP or carboplatin during CCRT for stage III NSCLC. Hematological grade 3 and 4 neutropenia is a major complication during CCRT and often delays and interrupts treatment. In more severe cases, grade 3 and 4 neutropenia can lead to treatment-related death. In most studies on platinum-based regimens combined with taxanes, the incidence of grade ≥ 3 neutropenia was often higher than 40%. In a previous study on NVBo plus CDDP with concomitant RT, treatment-related death occurred at induction CT with CDDP plus docetaxel. In contrast, in the current study, there was no treatment-related death, which was similar to another study in which NVBo plus CDDP was used in CCRT and induction therapy.

Resection is feasible for selected patients with stage III NSCLC who achieved PR or SD after neoadjuvant CCRT. Patients who underwent lobectomy after neoadjuvant CCRT had better survival than those who received definitive CCRT only. In the current study, 17 patients underwent resection after induction CCRT or consolidation therapy. One patient decided to opt for pneumonectomy.
PFS of patients who underwent surgery was 25.67 months. Considering the post-operative pathological findings, 15 patients had nodal downstaging and seven had pathological complete remission, six of whom are currently alive and disease-free. Thus, the results of the present study provide some perspectives regarding the treatment of patients with stage III NSCLC. First, NVBo plus CDDP with concomitant RT may be a potentially curative treatment for stage III NSCLC. Second, surgery may improve the outcomes with better local control and survival among selected patients with stage III NSCLC who received induction CCRT. All patients who underwent surgery in our study were reviewed and evaluated by multiple modality tumor boards, as selected patients with stage III NSCLC benefit from surgery after multidisciplinary evaluation and management.26,27
 
The role of consolidation CT after CCRT for locally advanced NSCLC still remains unclear. Consolidation CT may improve OS of patients with locally advanced NSCLC receiving CCRT, but not the response rate and PFS.28,29 Moreover, analysis failed to show evidence that CCRT provided any significant survival benefit for locally advanced NSCLC.30 However, our study commenced in January 2010, when the role of consolidation CT after CCRT was being investigated in several studies.22,31–33 Therefore, in our study, consolidation CT was administered in most patients whose tumors were inoperable after CCRT.
 
In conclusion, NVBo and CDDP with concomitant RT (i.e., CCRT) is an effective treatment for stage III NSCLC, with an acceptable toxicity profile. Surgery is feasible for selected patients who received CT with NVBo and CDDP as part of CCRT.

Acknowledgments

The authors wish to thank Ms. Ya-Wen Chiu and Ms. Li-Chuan Tsen in the Department of Nursing, and Ms. Shao-Hsuan Lin and Ms. Hsiao-Ying Yang in the Department of Thoracic Medicine and the Cancer Registry Center of Chang-Gung Memorial Hospital for their assistance in recording and retrieving of data of the patients with lung cancer.

This work was partially funded by Chang-Gung Memorial Hospital (CMRPG-3A0371, -3B0101, -3B0102, -3B0103, and CIRPG3D0281 ~ CIRPG3D0283 for Dr. C. Y. Liu; CMRPG-3B0091, -3B0092, -3B0093, and CIRPG3D0291 ~ CIRPG3D0293 for Dr. C. T. Yang; CIRPG3D0261 ~ CIRPG3D0263 for Dr. C. H. Chen; CIRPG3D0271 ~ CIRPG3D0273 for Dr. C. T. Wu; CIRPG3D0251 ~ CIRPG3D0253 for Dr. Y. C. Wu).

Disclosure

No authors report any conflict of interest.

Author contributions

The study was conceived and designed by Chih-Hung Chen, Chien-Ying Liu, and Cheng-Ta Yang. Data including patient referral, treatment planning, etc was acquired by all the authors. Ping-Chih Hsu and Chien-Ying Liu analysed and interpreted the data. Ping-Chih Hsu and Cheng-Ta Yang wrote, reviewed and revised the manuscript. The study was supervised by Chih-Hung Chen, Chien-Ying Liu, and Cheng-Ta Yang.

References

1. Alberg AJ, Brock MW, Samet JM. Epidemiology of lung cancer: Looking to the future. J Clin Oncol 2005; 23: 3175–85.
2. Jemal A, Bray F, Center MM, Ferlay J, Forman D, Mathers C. Global cancer statistics. CA Cancer J Clin 2011; 61: 69–90.
3. Pignon JP, Stewart LA. Randomized trials of radiotherapy alone versus combined chemotherapy and radiotherapy in stages IIIA and IIIB non small cell lung cancer: A meta-analysis. Cancer 1996; 77: 2413–4.
4. Price A. Emerging developments of chemoradiotherapy in stage III NSCLC. Nat Rev Clin Oncol 2012; 9: 591–8.
5. Biswas T, Sharma N, Machtay M. Controversies in the management of stage III non-small-cell lung cancer. Expert Rev Anticancer Ther 2014; 14: 333–47.
6. Vokes EE, Herndon JE, Crawford J et al. Randomized phase II study of cisplatin with gemcitabine or paclitaxel or vinorelbine as induction chemotherapy followed by concomitant chemoradiotherapy for stage IIIB non-small-cell lung cancer: Cancer and leukemia group B study 9431. J Clin Oncol 2002; 20: 4191–8.
7. Jassem J, Ramlau R, Karnicka-Mlodkowska H et al. A multicenter randomized phase II study of oral vs. intravenous vinorelbine in advanced non-small-cell lung cancer patients. Ann Oncol 2001; 12: 1375–81.
8. Flötten Ø, Grønberg BH, Sundstrom S, Helbækmo N, Bremnes R, von Plessen C. Oral versus intravenous vinorelbine in advanced NSCLC—A retrospective comparison. Cancer Treat Res Commun 2016; 9: 15–20.
9. Depierre A, Freyer G, Jassem J et al. Oral vinorelbine: Feasibility and safety profile. Ann Oncol 2001; 12: 1677–81.
10. Krzakowski M, Provencio M, Utracka-Hutka B et al. Oral vinorelbine and cisplatin as induction chemotherapy and concomitant chemoradiotherapy in stage III non-small cell lung cancer: Final results of an international phase II trial. J Thorac Oncol 2008; 3: 994–1002.
11. Descourt R, Vergnenegre A, Barlesi F et al. Oral vinorelbine and cisplatin with concurrent radiotherapy after induction chemotherapy with cisplatin and docetaxel for patients with locally advanced non-small cell lung cancer: The GFPC 05-03 study. J Thorac Oncol 2011; 6: 351–7.
12. Aupérin A, Le Péchoux C, Rolland E et al. Meta-analysis of concomitant versus sequential radiochemotherapy in locally advanced
advanced non-small-cell lung cancer. J Clin Oncol 2010; 28: 2181–90.
13 Beckmann G, Fietkau R, Huber RM et al. Oral vinorelbine and cisplatin with concomitant radiotherapy in stage III non-small cell lung cancer (NSCLC): A feasibility study. Onkologie 2006; 29: 137–42.
14 Cancer Therapy Evaluation Program, Common Terminology Criteria for Adverse Events, Version 3.0, DCTD, NCI, NIH, DHHS March 31, 2003. Available from URL: http://ctep.cancer.gov. Accessed date: August 9, 2006.
15 Tabchi S, Kassouf E, Rassy EE et al. Management of stage III non-small cell lung cancer. Semin Oncol 2017; 44: 163–77.
16 Furuse K, Fukuoka M, Kawahara M et al. Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small cell lung cancer. J Clin Oncol 1999; 17: 2692–9.
17 Robinson LA, Ruckdeschel JC, Wagner H Jr, Stevens CW, American College of Chest Physicians. Treatment of non-small cell lung cancer stage IIIA: ACCP evidence-based clinical practice guidelines (2nd edition). Chest 2007; 1332: 243–65.
18 Socinski MA, Rosenman JG, Schell MJ et al. Induction carboplatin/paclitaxel followed by concurrent carboplatin/paclitaxel and dose-escalating conformal thoracic radiation therapy in unresectable stage IIIA/B non-small cell lung carcinoma: A modified phase I trial. Cancer 2000; 89: 534–42.
19 Zatloukal P, Petruzelka L, Zemanova M et al. Concurrent versus sequential chemoradiotherapy with cisplatin and vinorelbine in locally advanced non-small cell lung cancer: A randomized study. Lung Cancer 2004; 46: 87–98.
20 Locher C, Pourel N, Le Caer H et al. Impact of a comprehensive geriatric assessment to manage elderly patients with locally advanced non-small-cell lung cancer: An open phase II study using concurrent cisplatin-oral vinorelbine and radiotherapy (GFPC 08-06). Lung Cancer 2018; 121: 25–9.
21 Lerouge D, Rivière A, Dansin E et al. A phase II study of cisplatin with intravenous and oral vinorelbine as induction chemotherapy followed by concomitant chemoradiotherapy with oral vinorelbine and cisplatin for locally advanced non-small cell lung cancer. BMC Cancer 2014; 14: 231.
22 Yamamoto N, Nakagawa K, Nishimura Y et al. Phase III study comparing second- and third-generation regimens with concurrent thoracic radiotherapy in patients with unresectable stage III non-small-cell lung cancer: West Japan thoracic oncology group WJTOG0105. J Clin Oncol 2010; 28: 3739–45.
23 Wang L, Wu S, Ou G et al. Randomized phase II study of concurrent cisplatin/etoposide or paclitaxel/carboplatin and thoracic radiotherapy in patients with stage III non-small cell lung cancer. Lung Cancer 2012; 77: 89–96.
24 Pless M, Stupp R, Ris HB et al. Induction chemoradiation in stage IIIA/N2 non-small-cell lung cancer: A phase 3 randomised trial. Lancet 2015; 386: 1049–56.
25 Yang KL, Chang YC, Ko HI et al. Optimizing survival of patients with marginally operable stage IIIA non-small-cell lung cancer receiving chemoradiotherapy with or without surgery. Clin Lung Cancer 2016; 17: 550–7.
26 Hofmann HS, Braess J, Leipelt S et al. Multimodality therapy in subclassified stage IIIA-N2 non-small cell lung cancer patients according to the Robinson classification: Heterogeneity and management. J Thorac Dis 2018; 10: 3585–94.
27 Tamburini N, Maniscalco P, Mazzara S et al. Multidisciplinary management improves survival at 1 year after surgical treatment for non-small-cell lung cancer: A propensity score-matched study. Eur J Cardiothorac Surg 2018; 53: 1199–204.
28 Wang X, Ding X, Kong D et al. The effect of consolidation chemotherapy after concurrent chemoradiotherapy on the survival of patients with locally advanced non-small cell lung cancer: A meta-analysis. Int J Clin Oncol 2017; 22: 229–36.
29 Liu L, Bi N, Ji Z et al. Consolidation chemotherapy may improve survival for patients with locally advanced non-small-cell lung cancer receiving concurrent chemoradiotherapy - retrospective analysis of 203 cases. BMC Cancer 2015; 15: 715.
30 Tsujino K, Kurata T, Yamamoto S et al. Is consolidation chemotherapy after concurrent chemo-radiotherapy beneficial for patients with locally advanced non-small-cell lung cancer? A pooled analysis of the literature. J Thorac Oncol 2013; 8: 1181–9.
31 Bastos BR, Hatoum GF, Walker GR et al. Efficacy and toxicity of chemoradiation with carboplatin and irinotecan followed by consolidation docetaxel for unresectable stage III non-small cell lung cancer. J Thorac Oncol 2010; 5: 533–9.
32 Mutlu H, Arslan D, Gündüz S et al. The optimal treatment modality in patients with T4N2M0 non-small cell lung cancer: The best choice may be definitive chemoradiotherapy followed by consolidation chemotherapy. Chemotherapy 2014; 60: 107–11.
33 Ahn JS, Ahn YC, Kim JH et al. Multinational randomized phase III trial with or without consolidation chemotherapy using docetaxel and cisplatin after concurrent chemoradiation in inoperable stage III non-small-cell lung cancer: KCSG-LU05-04. J Clin Oncol 2015; 33: 2660–6.
34 Albain KS, Swann RS, Rusch VW et al. Radiotherapy plus chemotherapy with or without surgical resection for stage III non-small-cell lung cancer: A phase III randomised controlled trial. Lancet 2009; 374: 379–86.

Supporting Information
Additional Supporting Information may be found in the online version of this article at the publisher’s website.

Table S1 Characteristics of 29 patients with progression-free survival (PFS) of <7 months.

Table S2 Sites of progression and treatment for the 29 patients with progression-free survival (PFS) of <7 months.